BioCentury
ARTICLE | Clinical News

EndoBarrier Gastrointestinal Liner endocrine/metabolic data

September 26, 2011 7:00 AM UTC

Data from 17 obese patients with Type II diabetes showed that EndoBarrier Gastrointestinal Liner significantly reduced mean HbA1c at week 24 by 1.4% from 8.4% at baseline (p<0.01), with an excess mean weight loss of 29.8%. EndoBarrier also significantly improved fasting glucose and significantly increased PYY and GLP-1 concentrations from baseline within 1 week of implantation (p<0.01 for all). Additionally, EndoBarrier eliminated or reduced the use of anti-diabetic medications in 16 of 17 patients. Data were presented at the European Association for the Study of Diabetes meeting in Lisbon. ...